Although all-trans retinoic acid (ATRA) can restore the differentiation capacity of leukemic promyelocytes, early leukemic myeloblasts are conversely not responsive to ATRA induced granulocytic differentiation. To assess whether this resistance to ATRA is related to an impaired function of the Retinoic Acid Receptor a (RARa), we performed an analysis of RARa expression and transactivation activity, in several myeloid leukemic cell lines, representative of different types of spontaneous acute myeloid leukemias. Our results indicate that a functionally active RARa nuclear receptor is expressed in all the analyzed cell lines, regardless of their differentiation capacity following exposure to ATRA. The observation that ATRA treatment is able to induce the expression of retinoic acid target genes, in late-but not in early-myeloblastic leukemic cells, raises the possibility that the differentiation block of these cells is achieved through a chromatin mediated mechanism. Acetylation is apparently not involved in this process, since the histone deacetylase inhibitor trichostatin A, is not able to restore the differentiation capacity of early leukemic myeloblasts. Further investigation is needed to clarify whether myeloid transcription factors, distinct to RARa, play a role in the resistance of these cells to ATRA treatment. Cell Death and Differentiation (2001) 8, 70 ± 82.
Introduction
Acute myeloid leukemias (AMLs) are heterogeneous neoplastic disorders arising from pluripotent hematopoietic stem cells, 1 that lead to accumulation of immature myeloid cells (leukemic blasts) in bone marrow, peripheral blood and other organs. The growth advantage of AML blasts is not simply realized through an increased proliferation activity, but mainly through a prolonged survival time, due to a maturation arrest, and, consequently, to an unefficient activation of the apoptotic program. 2 Several cytogenetic abnormalities have been described in different forms of AML, 3 generally resulting in the disruption of transcription factors that are involved in the regulation of normal myelopoiesis. 4 These cytogenetic abnormalities are supposed to contribute to the differentiation arrest of AML blasts, and the observation that distinct chromosomal aberrations may lead to the same leukemic phenotype, 5 suggests the existence of final common pathways for the transcriptional control of myeloid differentiation. 4 The French ± American ± British (FAB) classification 6 of AMLs, based on morphological, cytochemical and immunophenotypic 7 criteria, has clearly shown that maturation arrest of AML blast occurs at different stages of myeloid differentiation. Regardless of the stage of differentiation block, the possibility to induce AML cell maturation provides an opportunity to improve the clinical course of these malignancies. In spite of the physiological role exerted by colony stimulating factors (CSFs) in the regulation of normal myelopoiesis, these growth factors, besides being unable to induce the differentiation of AML cells, are also capable of stimulating the proliferative activity of such cells. 8 The use of CSFs in the differentiation therapy of AMLs is therefore controversial. 8, 9 Several chemical inducers, as all trans retinoic acid (ATRA) and 1a, 25 dihydroxyvitamin D3 (VD), are, on the other hand, able to overcome the maturation arrest of AML cells, leading to the induction of granulocytic and mono-macrophagic differentiation respectively. 10 These observations raise the question of the physiological role exerted by ATRA and VD in the regulation of normal hematopoiesis. In particular, ATRA delays the differentiation of primitive hematopoietic stem cells and, at the same time, enhances the terminal maturation of granulo-monocyte committed progenitors. 11 Besides these physiological effects ATRA is also a powerful differentiating agent for specific types of AML blast cells. In vitro studies have in fact shown that ATRA induces granulocytic differentiation of human late myeloblast cell lines, such as HL-60, 12 by interacting with RARa/RXR heterodimers. 13 The key role of RARa/RXR heterodimers in the control of myeloid differentiation is also supported by the observation that a dominant negative, or an overexpressed `wild-type' RARa receptor blocks neutrophil differentiation of primary myeloid cells at the promyelocyte stage, and this differentiation block can be overcome by treatment with ATRA. 14 ± 16 Furthermore ATRA can induce granulocytic differentiation, in vitro and in vivo, of acute promyelocytic leukemia (APL, or M3-AML) cells carrying the t (15;17) translocation. 17, 18 This genetic abnormality specifically occurs in the majority of APLs and generates the PML/RARa fusion gene. 19 ± 21 In a limited number of APL cases alternative chromosomal translocations have been described, like the t(11;17) which generates a distinct fusion gene named PLZF-RARa, and the t(5;17) that gives rise to the NPM-RARa fusion gene. 5 The aberrant recruitment of nuclear co-repressor complexes, containing N-CoR and histone deacetylase (HDAC), on promoter regions of RA target genes, has been claimed as a mechanism to explain the differentiation block of APL cells carrying PML/RARa or PLZFRARa fusion genes 22, 23 . More recently the aberrant recruitment of N-CoR/HDAC complexes on chromatin has also been proposed to be involved in the maturation arrest of M2 type AML cells carrying the t(8;21) translocation. 24 These observations open the possibility for a therapeutic use of HDAC inhibitors, like trichostatin A (TSA) and sodium butyrate, as differentiating agents for AML blasts. 25 AML types distinct to M3-AML (M0, M1, M2, M4 and M5) are not responsive to ATRA induced granulocytic differentiation. 26 Several myeloid cell lines have been established, starting from primary AML blasts, that maintain the peculiar differentiation block of the parental leukemic cells they derive from, and can therefore be considered interesting in vitro models to characterize the maturation arrest of AML cells. 27 To identify the molecular mechanisms underlying the resistance to ATRA induced differentiation, we investigated RARa nuclear receptor expression, phosphorylation, DNA binding capacity, transactivation activity and ability to induce a ligand dependent expression of RA target genes, in eight leukemic myeloid cell lines, representative of the maturation block occurring in different types of spontaneous AMLs. Our data indicate that only late myeloblastic/promelocytic leukemic blasts are responsive to ATRA induced granulocytic differentiation, underlining that specific maturation windows exist, permissive to the activity of physiological differentiation inducers. In spite of this, functional RARa/RXR heterodimers were detected in both ATRA responsive and non responsive myeloid leukemic populations.
Results

ATRA induced differentiation of myeloid cell lines arrested at different levels of maturation
Granulocytic differentiation was evaluated after 5 days of treatment with 10 76 M ATRA, monitoring CD11b and CD14 antigen expression and cell morphology. 27 As shown in Figure 1 , immature myeloblastic cell lines such as K562 (myelo-erythroblastic), KG1a (M0 type), KG1 (M1 type) and the more differentiated cell lines THP1 and U937 (M5 type), are substantially not responsive to ATRA induced granulocytic differentiation since no induction of CD11b surface antigen occurs after ATRA treatment. Conversely the myeloblastic cell lines HL60 (M2/M3 type) and NB4 (M3 type) are responsive to ATRA induced granulocytic differentiation, since a clear induction of CD11b is observed in these cells (Figure 1 ), which is not coupled to expression of CD14 (not shown). Morphological evaluation shows that only HL60 and NB4 cell lines assume a granulocytic morphology after 5 days of ATRA treatment (data not shown). Exposure of AML1 cells to ATRA resulted in a massive cell death which was quite evident after 48 h of treatment, as assessed by morphology, cytofluorimetric evaluation of the hypodiploid DNA content and gel electrophoresis, that showed the typical DNA fragmentation ladder pattern (data not shown). ATRA induced apoptosis of AML1 cells can probably be considered a partial response to ATRA, as already described for other myeloid cell lines. 28 
RARa protein expression
Western blot analysis, performed on NE before any treatment with ATRA, substantiates the presence of RARa protein bands in all the analyzed myeloid cell lines (Figure 2 ), implying that RARa is always expressed, regardless of the responsiveness to ATRA induced differentiation. Several RARa immuno-reactive protein bands are detected in the analyzed NE, having a molecular weight (MW) of 54, 57 and 58 kDa. A similar pattern of RARa protein expression has already been described in non hematopoietic cells. 29 In NB4 cells the 110 kDa PML-RARa fusion protein is also detectable, as expected ( Figure 2 Figure 3A,B) , according to the recent demonstration that ATRA triggers a rapid degradation of these proteins. 30 Our data indicate that, although at different levels, RARa protein is expressed in all the studied cell lines, showing that the expression of this nuclear receptor does not account for the different maturation capacity of the examined cell lines upon treatment with ATRA.
RARa protein phosphorylation
As already reported, different size RARa bands have been detected in the analyzed myeloid cell lines. To assess whether this complex pattern of RARa protein expression was depending on differential phosphorylation, a distinct Western blot analysis was performed using AP treated NE. In all the examined NE, digestion of the higher size 57 ± 58 kDa doublet with AP gives rise to a 54 kDa RARa band ( Figure  4A ± C, lanes 2 and 5), while treatment of the lower size 54 kDa RARa band with AP generates a 52 kDa RARa form ( Figure 4B , lane 2, C, lanes 2 and 5). The conversion to the de-phosphorylated 54 and 52 kDa RARa forms, is not observed when the analyzed NE are incubated in the same experimental conditions but in absence of the AP enzyme, excluding the possibility of a nonspecific degradation of the detected RARa protein bands ( Figure 4A ± C, lanes 3 and 6). The 57 ± 58 and 54 kDa RARa forms still maintain different sizes following dephosphorylation with AP, that are 54 and 52 kDa respectively. RT ± PCR experiments, performed to specifically detect RARa1 and RARa2 isoforms, 31 showed that they are simultaneously expressed in all the examined cell lines (data not shown), suggesting that these isoforms are not responsible for the expression pattern of the two dephosphorylated 54 and 52 kDa RARa proteins.
These results clearly demonstrate that, although at different levels, RARa is phosphorylated in all the analyzed cell contexts.
RARa DNA binding capacity
To assess whether response to ATRA treatment of the analyzed myeloid cell lines resides in a differential DNA binding capacity of RARa/RXR heterodimers, we performed EMSA experiments in which NE were challenged with a RARE-b2 oligonucleotide. In all the EMSA experiments, specificity of the shifted bands was confirmed by formation of a supershift complex, or by inhibition of the basal complex, following addition of an anti-RARa monoclonal Ab. An anti-RXR monoclonal Ab was, in turn, able to substantiate a supershifted band when RXR was complexed with RARa in a heterodimeric conformation. The addition of an isotype control Ab to some of the tested NE did not modify the band shift profile, as expected ( Figure 5A, lanes 4 and 8) , showing that the changes of EMSA pattern produced by the anti-RARa and anti-RXR Ab were specific. In several control experiments specificity of the shift complexes was also confirmed by adding 100-fold excess of cold RARE-b2 oligonucleotides (data not shown). As shown in Figure 5B Figure 5B , lanes 7, 10, 13, 16, 19, 22 and 25) . These data clearly show that, when NE of the analyzed cell lines are challenged with a RARE-b2 oligomer, a shift complex containing RARa/RXR heterodimers is formed. An exception is perhaps represented by K562 cells, where the basal shift complex is only to a minor extent depending on RARa/RXR heterodimers, consistently with the low abundance of RARa protein, substantiated in these cells by Western blot analysis.
However, it is possible to conclude that ATRA induced maturation capacity of the analyzed myeloid cell lines cannot be ascribed to a differential DNA binding capacity of RARa/RXR heterodimers, since all the examined NE are able to form RARa/RXR dependent gel shift complexes.
Transactivation activity of RARa/RXR heterodimers on an exogenous RARE-b2 dependent expression vector
To evaluate the transactivation capacity of RARa/RXR heterodimers in the different cell contexts, we performed transient transfection assays with a plasmid construct in which the reporter gene was expressed under the control of a RARE-b2 element. As shown in Figure 6 , ligand dependent transcriptional activation of the reporter gene occurs in all transfected cell lines, independently on their ability to differentiate after ATRA treatment. The extent of ATRA induced transcriptional activation varies from a 4 ± 5-fold induction in K562, KG1a and KG1 cells, to a 8 ± 14-fold induction in HL60, NB4, THP1 and U937 ( Figure 7 ). Again, it is possible to conclude that the transactivation activity of RARa/ RXR heterodimers does not correlate with the capacity of the analyzed cell lines to undergo granulocytic differentiation following ATRA treatment.
Transactivation activity of RARa/RXR heterodimers on endogenous RA target genes
Our results so far indicate that RARa/RXR heterodimers are able to bind a RARE-b2 element, and to transactivate an exogenous RARE-b2 carrying expression vector, in RA unresponsive myeloid cell lines. To assess if RARa/RXR heterodimers are also able to transactivate endogenous RA target genes in ATRA unresponsive cell contexts, we performed a Northern blot analysis after a short treatment with ATRA. Among the RA target genes, we assessed the expression of IRF-1 and E3 genes, which have been shown to be associated with granulocytic differentiation. 32, 33 Results shown in Figure 8 gene, observed in ATRA treated AML1 cells, is consistent with the activation of the apoptotic program, observed in these cells, since IRF-1 has also been proposed to be involved in apoptosis. 34 
Treatment of the analyzed cell lines with trichostatin A
The discrepancy between the capacity of RARa/RXR heterodimers to transactivate an exogenous RARE-b2 Figure 5 EMSA analysis performed by challenging nuclear extracts (NE) of the analyzed myeloid cell lines with a 32 P-labeled RARE b2 probe. The observed major shift complexes are indicated by arrows. The examined cell lines, and the added Ab, are reported at the top of each autoradiogram. To assess whether RARa and RXR proteins participated to the formation of shift complexes, NE were respectively challenged with an anti-RARa (RARa Ab) or an anti-RXRa, b, g (RXR Ab) antibody. (A) shows a control experiment, in which the effect of an isotype control (IC) Ab, on the band shift profile of U937 and K562 cells (lanes 4 and 8, respectively), is compared to the EMSA pattern specifically promoted by addition of anti-RARa (lanes 3 and 6) and anti-RXR Ab (lanes 2 and 7). (B) shows the EMSA results obtained in all the analyzed cell lines. In lane 1, the migration pattern of unincubated RARE b2 oligomer (C) is reported dependent promoter and the inability to activate the transcription of endogenous RA target genes, raises the possibility that the differentiation block observed in early leukemic ATRA non responsive myeloblasts, might reside in a chromatin mediated transcription repression. Histone deacetylation induced by histone deacetylase (HDAC) has been demonstrated to be an important mechanism of transcriptional regulation that leads to changes in chromatin conformation and to transcription repression. 35 We therefore investigated if the HDAC inhibitor trichostatin A (TSA), was able to restore ATRA induced granulocytic differentiation of the more undifferentiated myeloid cell lines (K562, KG1a and KG1).
For this purpose cell lines were treated with 200 ng/ml TSA and 10 76 M ATRA, separately or in association. Differentiation was then assessed by morphology (MGG staining), cytofluorimetric analysis (CD11b expression), NBT reduction assay and type II transglutaminase (TGase) mRNA expresion, as described. 22, 23 A 5 days treatment of HL-60 and NB4 cells with ATRA/TSA, clearly enhanced the percentage of the more differentiated myeloid elements (metamyelocytes, band granulocytes and granulocytes), as compared to the same cells treated with ATRA alone (40 ± 55% versus 15 ± 30% respectively) (not shown). Conversely none of the other Differentiation of HL-60 and NB4 cells with ATRA, resulted in a clear induction of NBT positivity (from 8 to 63% and from 0 to 34%, respectively) ( Figure 10 ). Furthermore TSA treatment of NB4 cells increased the differentiation effect obtained by ATRA alone (from 34 to 83%) (Figure 10) , as already described. 23 What we observed in the more undifferentiated myeloid cell lines such as K562, KG1a and KG1 is that neither treatment with ATRA alone, nor stimulation with ATRA/TSA, was able to An increased NBT positivity was instead detected upon treatment with ATRA of the monoblastic THP1 cell line (from 0 to 31%), which was not enhanced by TSA addition (Figure 10 ), and was coupled with a weak induction of CD14 antigen (about 40% positive cells; not shown). These last results could be explained by the already described capacity of monoblastic cell lines to undergo monomacrophagic differentiation following treatment with ATRA alone 36, 37 or ATRA/VD association.
± 40
The expression of TGase, a RA target gene 41, 42 has been shown to be up-regulated following ATRA treatment of NB4 cells. 43 Furthermore this transcriptional activation is enhanced by simultaneous exposure to TSA. 22 To investigate if the combined treatment with ATRA and TSA was able, even partially, to activate the genetic program underlying granulocytic differentiation, we used the highly 
Discussion
AMLs are heterogeneous neoplastic disorders characterized by the accumulation of a large number of leukemic blasts that fail to mature into functional, terminally differentiated, granulocytes or monocytes. 2 The majority of AMLs carry cytogenetic abnormalities, that are supposed to contribute to the maturation arrest. 5 These chromosomal aberrations are extremely heterogeneous 3 and no tight association can be established between genetic abnormalities and the different AML phenotypes, the only exception being represented by APLs characterized by the PML-RARa fusion gene. 5 An efficacious therapeutic approach for AML is provided by the possibility to overcome the differentiation block of leukemic blast cells. 9 APLs harboring the PML-RARa fusion gene represent a clear evidence of successful differentiation therapy achieved with ATRA. 17, 18 Furthermore innovative therapeutic perspectives could be opened, in the future, by compounds which are able to modify chromatin conformation, like HDAC and DNA methyltransferase inhibitors. 25 As mentioned above, AMLs having phenotypes distinct to M3-AML, for example M0/M1 type or M5 type blast cells, are not responsive to ATRA induced granulocytic differentiation. 26 To investigate the molecular mechanisms underlying such resistance to ATRA treatment we have analyzed RARa expression and function in several myeloid leukemic cell lines, that are representative of various FAB cytotypes, and more precisely: K562 (myelo-erythroid), KG1a and KG1 (M0/ Our results demonstrate that RARa protein is expressed, phosphorylated and able to heterodimerize with RXR, in all the analyzed myeloid cell populations, regardless of their responsiveness to ATRA. Furthermore RARa/RXR heterodimers are able to bind a RARE-b2 element and to transactivate a RARE-b2 dependent expression vector following interaction with ligand, in both ATRA responsive (M2/M3 and M3) and non responsive (M0/M1 and M5) cell contexts. On the other hand, the expression of endogenous RA target genes, as IRF1 and E3, is rapidly induced in the more differentiated analyzed cell lines, either ATRA responsive (M2/M3 and M3 type) or non responsive (M5 type), but not in the more undifferentiated ATRA unresponsive cell contexts (myelo-erythroid precursors and M0/M1 early myeloblasts). In these last cell lines treatment with ATRA also fails to induce the expression of TGase, another RA target gene. An interesting association emerges, from our data, between the transcriptional response induced by ATRA, and the presence of the lower size 54 kDa RARa form, in the more differentiated M2/M3 and M5 type cells. These cells are in fact characterized by a clear induction of RA target genes and a high efficiency of ATRA dependent transactivation, suggesting that the lower size 54 kDa RARa form could be more efficient in terms of transcriptional activity, as compared to the higher size 57 ± 58 kDa RARa doublet. The absence of the 54 kDa size RARa protein in NB4 cells is not surprising, to this regard, since several evidences suggests that ATRA effects are mainly mediated by the PML-RARa chimeric protein in this cells. 44 The 57 ± 58 and 54 kDa RARa forms still have a different size upon digestion of NE with AP (54 and 52 kDa respectively), showing that phosphorylation is not entirely responsible for the observed pattern of RARa expression. The expression of different RARa isoforms could, in principle, account for these findings. Although seven distinct RARa isoforms have been identified in the mouse, 45 only the RARa1 and RARa2 isoforms have been, to date, characterized in human cells. RT ± PCR experiments, performed using oligonucleotide primers able to detect the human RARa1 and RARa2 isoforms, 31 showed that they are simultaneously expressed in all the examined cell lines (data not shown), as already demonstrated for normal bone marrow and APL cells. 31 Other RARa isoforms, distinct to RARa1 and RARa2, could however explain the presence of a differential pattern of RARa protein expression among the analyzed cell populations. It has to be pointed out that ATRA up-regulates the expression of RA target genes not only in M2-M3 type cells, but also in M5 type cells, as already reported by others, 32, 38 implying that this differentiation inducer is able to modulate the expression of RA responsive genes, regardless of its ability to promote granulocytic differentiation. This is not surprising, since THP1 and U937 cells, being already committed along the mono-macrophage maturation pathway, probably cannot undergo granulocytic differentiation. An intriguing observation is provided, to this regard, by the capacity of ATRA to trigger mono-macrophagic differentiation of M5 type cell lines, 36, 37 or to potentiate VD induced mono-macrophagic differentiation of the same cells. 40, 46 Besides promoting mono-macrophagic differentiation of leukemic monoblasts, ATRA also induces the monocytic differentiation of M2 type blast cells. 47 The molecular mechanisms underlying the differentiation effect exerted by ATRA on M5 and M2 type blast cells, are poorly understood, but these findings may represent a further observation supporting the existence of an interplay between RA and VD intracellular pathways. 38, 46, 47 A complete RA response pathway is not maintained in the more undifferentiated ATRA non responsive (myelo-erythroid and M0/M1) cell lines, where in spite of the presence of transcriptionally active RARa/RXR heterodimers, ATRA is unable to induce the expression of endogenous RA target genes. The discrepancy between the capacity of RARa/RXR heterodimers to transactivate an exogenous RARE-b2 dependent vector and the inability to activate the transcription of endogenous RA target genes in M0/M1 type cells, rises the possibility that the differentiation block of these cells might reside in a chromatin mediated transcription repression. RARa/RXR heterodimers, in their unliganded form, have been described to repress the transcription of RA target genes, by recruiting co-repressor complexes containing HDAC, that in turn induces a modification of chromatin which is not permissive for transcription. 48 The ability of RARa to behave as a transcriptional repressor is also supported by the recent observation that overexpression of a wild-type RARa in primary hematopoietic stem cells, leads to a block of granulocytic differentiation. 16 To assess the possible involvement of co-repressor complexes in maturation arrest of highly undifferentiated myeloid cell contexts, we investigated whether the HDAC inhibitor trichostatin A (TSA) was able to restore ATRA induced granulocytic differentiation of K562, KG1a and KG1 cell lines. Cell lines were then treated with TSA, ATRA or ATRA/TSA for 3 ± 5 days, and then differentiation was estimated by immunophenotypic analysis, NBT reduction assay and morphology. A clear synergism between ATRA and TSA was observed after induction of granulocytic differentiation in ATRA responsive NB4 and HL-60 cells, at least as assessed by morphology and NBT positivity. TSA treatment of NB4 cells also slightly enhanced ATRA induced expression of CD11b surface antigen. No ATRA/TSA synergism was detected when differentiation of HL-60 cells was evaluated by CD11b expression. This result is not surprising and it has already been reported by other authors, using comparable concentrations of the two compounds. 48 Conversely in the other ATRA unresponsive cell lines, treatment with TSA is not able to re-activate ATRA induced granulocytic differentiation, showing that the differentiation block of early myeloblastic AMLs, besides being resistant to ATRA, is also TSA insensitive. TSA treatment of K562, KG1a and KG1 cells, in fact, was not only unable to restore a phenotypic response to ATRA, assessed by CD11b expression, NBT reduction and morphology, but it was also unable to activate the genetic program that leads to ATRA induced granulocytic differentiation, as shown by RT ± PCR analysis of TGase mRNA expression. These findings are in agreement with the observation that TSA also fails to restore the differentiation capacity of M2 type blast cells carrying the t(8;21) translocation. 24 Moreover they can be considered a further evidence supporting the hypothesis that histone acetylation facilitates transcription but is not sufficient to induce the transcription of an inactive gene. 35 Taken together our data suggest that the control of granulocytic differentiation, in the early stages of leukemic myelopoiesis, might be regulated at the chromatin structure level by a mechanism that is apparently HDAC independent and might be represented, at least partly, by a reduced access of RARa/RXR heterodimers to promoter regions of RA target genes. This hypothesis is also supported by the already reported observation that early leukemic myeloblasts express functional vitamin D3 receptors (VDR), but are unable to differentiate after treatment with VD. 49 Apart from RARa, other transcription factors, such as PU.1, AML1 and C/EBPa, are involved in the regulation of myeloid differentiation. 4 Furthermore, several transcription regulatory elements, including the RAREs, have been shown to lie inside the promoter region of certain myeloid related genes, allowing to hypothesize that the expression of such genes is cooperatively activated by the interested transcription factors. Examples of this hypothetic cooperation are represented by CD11b, myeloperoxidase and lactoferrin genes. 50 Based on these considerations we cannot exclude that a functional impairment of myeloid transcription factors, distinct to RARa, may also play a role in the resistance to ATRA induced differentiation of M0/M1 cells.
Further studies are necessary to clarify the molecular mechanisms underlying the maturation arrest of M0-M1 leukemic myeloblasts, in order to develop new differentiation strategies.
Materials and Methods
Cell cultures
The following hematopoietic cell lines were obtained from ATCC: K562 (myelo-erythroid precursors), KG1a (M0 type), KG1 (M1 type), AML1 and HL60 (M2-M3 type), NB4 (M3 type), THP1 (M5 type), U937 (histiocytic cells), and cultured in RPMI 1640 medium (GIBCO B.R.L., Life Technologies Inc., Gaithersburg, MD, USA), supplemented with 10% fetal calf serum (FCS) (GIBCO B.R.L.) and 2 mM L-glutamine (GIBCO B.R.L.). Differentiation was induced by treatment with 10 76 M ATRA (Hoffman-La Roche, Basel, Switzerland) and monitored by May Gru È nwald Giemsa (MGG) staining, immunophenotypic analysis and NBT reduction assay, performed as described. 12 When indicated, inhibition of HDAC activity was achieved by incubating cell cultures with TSA (Sigma, St. Louis, MO, USA) at concentrations ranging from 50 ± 200 ng/ml. The data presented in the Results section have been obtained with the higher concentration (200 ng/ml). With the only exception being U937 cells, that underwent a massive cell death following TSA treatment (at least at concentrations as high as 200 ng/ ml), cell viability of the other cell samples, upon exposure to TSA, was generally high.
Flow cytometry
Cytofluorimetric analysis of surface antigen expression was performed as described. 51 The following monoclonal antibodies (MoAb) were used for labeling cell samples: phycoerythrin-conjugated (PE) mouse anti-human CD11b (Becton Dickinson Immuno-cytochemistry Systems, San Jose, CA, USA), mouse anti-human CD14 PE (Becton Dickinson). Briefly each antibody was incubated at the proper dilution with cell samples in PBS containing 5% FCS for 30 min at 48C. Cells were then washed twice, resuspended with PBS and analyzed by a Coulter Epics XL flow cytometer (Coulter Electronics Inc., Hialeah, FL, USA). Assessment of apoptosis was performed by flow cytometry as already described. 52 
Nuclear extract preparation
Nuclear extracts (NE) of the analyzed cell populations, before and after treatment with ATRA, were obtained as already described, 53 with minor modifications. 49 Protein concentration was evaluated by the Lowry method. De-phosphorylation was obtained by diluting NEs fourfold in gel shift buffer and incubating at 378C for 30 min in the presence of calf intestine alkaline phosphatase (AP) (Promega, Madison, WI, USA). 29 As control, nuclear extracts were also incubated in the same experimental conditions without AP to exclude a nonspecific degradation of the nuclear receptor.
Western blotting
Expression of RARa protein in NE of the studied cell lines was performed by Western blot analysis as described 54 with some modifications. 49 Briefly: 50 mg of NE of each sample were dissolved in 16 reducing loading buffer (50 mM Tris pH 8, 5% bmercaptoethanol, 2% SDS, 0.1% Bromophenol Blue, 10% glycerol), loaded onto 7.5 ± 10% SDS ± PAGE and electrophoresed in TGS buffer (25 mM Tris pH 8.3, 250 mM glycine, 0.1% SDS). The separated proteins were transferred at 48C onto a nitrocellulose sheet by electroblotting procedure in TGM buffer (25 mM Tris pH 8.3, 250 mM glycine, 20% methanol) for 2 h at 1 A. In order to monitor the electroblotting efficiency the membrane was stained in 0.2% Ponceau S/0.3% TCA and destained in 0.3% TCA. Membranes were preblocked in blocking solution (10 mM Tris pH 8, 150 mM NaCl, 0.05% Tween 20, TBST, supplemented with 4 mg/ml normal serum) for 1 h at room temperature (rt), incubated for 1 h at rt with a 1 : 500 dilution of the RPa (F) rabbit policlonal anti-RARa primary antibody (kindly provided by Dr. P Chambon) and then with the indicated secondary antibody HRPconjugated (1 : 5000) (1 h at rt) in blocking solution. The detection was carried out by ECL method.
Gel shift assay
All the oligonucleotides were synthesized with an automated solid phase DNA sinthesizer (Applied Biosystem, Inc., Foster City, CA, USA; Mod. 394 A) with the standard phosphoramidite chemistry, purified by several extractions with NH 4 OH, incubated at 568C for 16 h, and ethanol precipitated or purified by PAGE. The following single stranded oligomers, already reported by other authors 55 and their complement were synthesized to be used as probes in the gel shift assay: 5'-TCGACGGGTAGGGTTCACCGAAAGTTCACTCGC, RARE-b2; 5'-AGCTTCAGGTCACCAGGAGGTCAGAGAGC, DR5. These oligonucleotides were purified by PAGE following by electroelution, and annealed in equimolar amounts, as previously described. 56 The double stranded oligodeoxynucleotides, again purified by PAGE and electroelution, were end labeled (100 ng) adding to 56 kinase buffer (0.25 M Tris-HCl, pH 7.5, 0.1 M MgCl 2 , 50 mM dithiothreitol, 1 mM spermidine, and 1 mM EDTA), [g 32 P]ATP (50 mCi; specific activity 3000 Ci/mmol) and 10 U of T4 polynucleotide kinase (Promega, Madison, WI, USA), to a final volume of 20 ml. The mixture was incubated at 378C for 1 h followed by extraction with 1 volume of 1 : 1 phenol/chloroform and ethanol precipitation. Specific radioactivities ranged from 1 ± 3610 8 c.p.m./mg DNA. Electrophoretic mobility shift assay (EMSA) was performed as described. 49 Briefly, NE (15 mg protein) were incubated with 5 mg poly (I:C) (Pharmacia, Piscataway, NJ, USA), for 20 min at room temperature in 16gel shift buffer (10 mM Tris-HCl pH 7.5, 50 mM KCl, 5 mM MgCl 2 , 1 mM DTT, 1 mM EDTA and 15% glycerol). The labeled oligonucleotide was then added (1 ng) prolonging the incubation for 30 min (final volume 20 ml). When indicated, specific antibodies were added to the incubation mixture 10 min before the addition of the probe. Specificity of the shift complexes was also confirmed by adding 100-fold excess cold RARE-b2 or DR5 oligonucleotides or an isotype control antibody (mouse IgG) (Becton Dickinson). The following antibodies were used: Ab9a (F) (mouse monoclonal anti-RARa, kindly provided by Dr. P Chambon); RX-1D12 (mouse monoclonal anti-RXRa,-b,-g, kindly provided by Dr. P Chambon). All the antibodies were added to the samples 1 : 20. The reaction mixtures were then electrophoresed on a 5% polyacrylamide gel in 0.56TBE (45 mM Tris base, 45 mM boric acid, 4 mM EDTA), pre-run for 1 h at room temperature. Finally the gel was fixed, dried in a vacuum essicator, and exposed to X-ray films (2 ± 4 h).
RNA analysis
Total cellular RNA was extracted using a modification of the guanidinium ± cesium chloride centrifugation technique. 57 For Northern blot analysis RNA samples were electrophoresed on 1% agaroseformaldehyde, blotted to nylon membranes and then hybridized with full length cDNA probes of IRF1, 32 E3 33 and GAPDH gene, 58 after [ 32 P] multiprime labeling. The synthesized oligomers used as primers in the RT ± PCR analysis were previously compared with the NIH gene bank by DNAsis software (Hitachi, Brisbaine, CA, USA) in order to avoid homologies with other gene sequences. For all the analyzed genes, oligonucleotides primers were designed on distinct exons, in order to exclude a possible genomic DNA contamination of the RNA samples. Messenger RNA expression of type II transglutaminase (TGase) gene was analyzed by RT ± PCR, performed as previously reported, 59 using the following oligonucleotide primers: TGase direct primer (DP), 5' -AATCTCA-CGGAGGGTCTCGGC-3'; TGase reverse primer (RP), 5'-CCGAGTCCAG-GTACACAGCATCC-3'. Normalization of amplified RNAs was carried out by means of the b2 microglobulin (b2m)`housekeeping' gene, performing a RT ± PCR reaction in which the following oligonucleotide primers were used: b2m DP, 5'-CTCGCGCTACTCTC-TCTTTC-T-3'; b2m RP, 5'-TCCATTCTT-CAGTAAGTCAACT-3'. Distinct direct primers were used for RT ± PCR analysis of RARa1 and RARa2 isoforms (RARa1 DP and RARa2 DP, respectively), in combination with a common reverse primer (RARa1-2 RP), as already reported by others. 31 These oligonucleotide primers were as follows: RARa1 DP 5'-GCCAGGCGCTCTGACCACTC-3'; RARa2 DP 5'-CCACCCCTAATCCCTTCCTA-3'; RARa1-2 RP 5'-AGCCCTTGCAGCCCTCACAG-3'.
Cell transfection
The following plasmids were used in the transfection experiments: (1) pCMVb (Clontech Laboratories Inc., Palo Alto, CA, USA), a bgalactosidase (b-gal) expression vector; (2) pTK/RAREb2-CAT (kindly provided by V Colantuoni), containing the chloramphenicol acetyltransferase (CAT) reporter gene under the control of the RAREb2 enhancer and the minimal promoter region of the human TK gene (7104/+51). 2.5610 7 cells were transfected by electroporation with 30 mg of pTK/RAREb2-CAT and 5 mg of pCMVb plasmid. Electroporation was performed at 250 V and 960 mF (Gene Pulser Apparatus, BioRad, Hercules, CA, USA). Transfected cells were cultured for 48 h in RPMI 1640 medium containing 15% FCS, with or without 10 76 M ATRA and then harvested for CAT assays, performed using radiolabeled chloramphenicol. 49 b-gal activity was used to normalize the amount of cell extract to be assayed for CAT activity.
